Comparison
Selank vs Sermorelin
Side-by-side of Selank and Sermorelin. Every row below is pulled from the compound schema and will update as our data grows. For deeper reads, follow through to each compound page.
Selank
Selank peptide benefits: tuftsin analog heptapeptide, intranasal anxiolytic and nootropic. Russian clinical data, dosing, half-life, safety.
Sermorelin
Sermorelin peptide therapy uses a 29-amino-acid GHRH analog to raise endogenous GH. Dosing, half-life, sermorelin vs ipamorelin, and safety.
Effects at a glance
Selank
- •Synthetic heptapeptide analog of tuftsin developed in Russia in the 1990s
- •Approved in Russia for generalized anxiety disorder and asthenic conditions
- •Russian RCTs report anxiolytic effects comparable to medazepam without sedation or dependence
- •Modulates GABAergic and serotonergic signaling and BDNF expression in preclinical models
- •Most commonly administered intranasally; subcutaneous use is anecdotal
- •No Western-validated trials; not FDA approved; research-use-only outside Russia
Sermorelin
- •Synthetic 29-amino-acid GHRH fragment; FDA approved 1997 for pediatric GH deficiency as Geref
- •Voluntarily discontinued by Serono in 2008 for commercial reasons; not safety-related
- •Compounded by 503A/503B pharmacies for off-label adult anti-aging and body-composition use
- •Produces physiologic pulsatile GH release; ~10 to 20 minute plasma half-life
- •Standard anti-aging clinic protocol: 200 to 500 mcg subcutaneously pre-bed, often with ipamorelin
- •Banned by WADA under S2 (peptide hormones, growth factors)
Side-by-side
| Attribute | Selank | Sermorelin |
|---|---|---|
| Category | peptide | peptide |
| Also known as | TP-7, Tuftsin analog | Sermorelin acetate, GRF 1-29, Geref, GHRH (1-29) NH2 |
| Half-life (hr) ↗ | 0.5 | 0.25 |
| Typical dose (mg) ↗ | 0.4 | 0.3 |
| Dosing frequency | 2-3x daily (intranasal) | 1-2x daily |
| Routes | intranasal, subcutaneous | subcutaneous |
| Onset (hr) | 0.25 | 0.25 |
| Peak (hr) | 1 | 0.5 |
| Molecular weight | 751.85 | 3357.88 |
| Molecular formula | C33H57N11O9 | C149H246N44O42S |
| Mechanism | Modulates GABAergic, serotonergic, and dopaminergic signaling. Increases BDNF expression in hippocampal neurons in preclinical models. Modulates enkephalin levels and immune cytokine signaling via tuftsin-like activity. | Synthetic 29-amino-acid GHRH fragment that binds the GHRH receptor on pituitary somatotrophs to stimulate endogenous pulsatile GH synthesis and release while preserving the GH-IGF-1 negative feedback loop. |
| Legal status | Approved as a prescription anxiolytic in Russia; not FDA approved; research-use-only grey market in most other jurisdictions | FDA approved 1997 (Geref, pediatric GHD); voluntarily discontinued by Serono 2008; compounded by 503A/503B pharmacies for off-label adult use; banned by WADA |
| WADA status | unknown | banned |
| DEA / Rx | Not FDA approved; not scheduled; research-chemical status outside Russia | Rx only via compounding (no controlled-substance schedule) |
| Pregnancy | Not recommended; insufficient data | Category C (historical labeling); not recommended in pregnancy |
| CAS | 129954-34-3 | 86168-78-7 |
| PubChem CID | 11765600 | 16129617 |
| Wikidata | Q4416793 | Q416620 |
Safety profile
Selank
Common side effects
- mild nasal irritation (intranasal)
- transient drowsiness (uncommon)
- mild headache
Contraindications
- pregnancy
- lactation
- severe psychiatric disorder (insufficient data)
Interactions
- benzodiazepines: additive anxiolytic effect; potential for over-sedation when stacked(moderate)
- SSRIs: no documented adverse interaction; co-administration described in Russian protocols(minor)
Sermorelin
Common side effects
- injection-site pain or irritation
- transient flushing
- headache
- vivid dreams (pre-bed dosing)
Contraindications
- pregnancy
- active malignancy
- history of pituitary tumor
- diabetic retinopathy (theoretical)
- untreated hypothyroidism
Interactions
- ipamorelin: synergistic GH release via parallel GHRH and ghrelin pathways; standard anti-aging clinic pairing(minor)
- CJC-1295: pharmacologically redundant (both GHRH-pathway); typically not stacked(minor)
- insulin: sustained GH can blunt insulin sensitivity over weeks(moderate)
- corticosteroids: blunt GH response; reduce expected efficacy(moderate)
- levothyroxine (untreated hypothyroidism): untreated hypothyroidism blunts GH response; correct thyroid first(moderate)
Which Should You Take?
Sermorelin comes out ahead for most readers on the criteria we weight: 3 catalogued goals, FDA approved 1997 (Geref, pediatric GHD); voluntarily discontinued by Serono 2008; compounded by 503A/503B pharmacies for off-label adult use; banned by WADA, with a Tier-A outcome catalogued. Selank is the right call when one of the conditionals below applies.
- → If your priority is focus or working memory, pick Selank.
- → If your priority is anxiety reduction, pick Selank.
- → If your priority is growth-hormone axis, pick Sermorelin.
- → If your priority is healthspan extension, pick Sermorelin.
Default choice: Sermorelin. Wider use case, a Tier-A evidence outcome catalogued, and broader goal coverage. Reach for Selank only if your priority sits squarely in the goals it owns above.
This verdict is generated from each compound's schema (goals, legal status, evidence outcomes, dosing route). It updates automatically as our compound data evolves; the deeper read sits on each individual compound page.
Common questions
What is the difference between Selank and Sermorelin?
Selank and Sermorelin differ in category (peptide vs peptide), mechanism, and typical dosing. See the side-by-side table for full details.
Which has a longer half-life, Selank or Sermorelin?
Selank half-life is 0.5 hours; Sermorelin half-life is 0.25 hours.
Can you stack Selank with Sermorelin?
Stack compatibility depends on mechanism overlap, legal status, and individual response. Check each compound page for specific interactions and contraindications before combining.
Go deeper